Go beyond the two GLP-1s everyone prescribes.
The incretin landscape is exploding — dual and triple agonists, amylin analogs, oral agents. Pepacorn keeps the whole class straight, with evidence, dosing, and the safety signals that matter.
Built for how you work
Semaglutide and tirzepatide are just the start — patients ask about what's next.
Side-by-side, evidence-graded write-ups across the full incretin and metabolic class.
Weight programs live and die on adherence and side-effect management.
Dosing detail, titration notes, and enforced cautions (including the MTC/MEN2 boxed warning) at the point of care.
You're tracking outcomes across a large patient panel.
Per-patient protocols, progress, and a peer outcome registry — built for a metabolic panel at scale.
The compounds your patients ask about
Each links to its full evidence-graded monograph — mechanism, dosing, cautions, and the research behind it.
Conditions you'll recognize
Jump into the explorer to see candidate agents ranked by role and evidence, with enforced cautions.
Bring precision-therapeutics decision support into your practice.
Evidence, cautions, protocols, and peer outcomes — decision support, not prescription. You decide.